Search Results

Arsenal Medical today announced enrollment of the first patient with the company’s investigational NeoCast™ embolic biomaterial.

Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.

Arsenal Biosciences, Inc. (ArsenalBio) today announced that Ken Drazan, MD, the company’s Chairman and Chief Executive Officer, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:30 a.m. PT.

Arsenal Biosciences, Inc. today announced that the first patient has been dosed with AB-2100 in a multi-center, open-label Phase 1/2 clinical trial for patients with clear-cell renal cell carcinoma (ccRCC).

Fortrea, a leading global contract research organization, announced it has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical and Fortrea Patient Access businesses, to Arsenal Capital Partners, a leading private equity firm specializing in building market-leading, technology-rich healthcare companies.

In 17 identical letters posted to his Truth Social account, the president said companies must lower their prices or the government ‘will deploy every tool in our arsenal to protect American families from continued drug pricing practices.’

Intricon completes construction of its Evolution Free Zone location, combines with Minnetronix Medical, and will fly the Forj Medical flag at its new site; equipment and workforce move into place for the grand opening